review Open AccessTop 1% cited

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Leukemia · 2022 · Vol. 36(7) · pp. 1703–1719

Joseph D. Khoury✉(The University of Texas MD Anderson Cancer Center)Éric Solary✉(Université Paris-Saclay)Oussama Abla(Hospital for Sick Children)Yassmine Akkari(Nationwide Children's Hospital)Rita Alaggio(Bambino Gesù Children's Hospital)Jane F. Apperley(Imperial College London)Rafael Bejar(University of California San Diego)Emilio Berti(University of Milan)Lambert Busque(Hôpital Maisonneuve-Rosemont)John K. C. Chan(Queen Elizabeth Hospital)Weina Chen(The University of Texas Southwestern Medical Center)Xueyan Chen(University of Washington)Wee Joo Chng(National University Cancer Institute, Singapore)John Choi(University of Alabama at Birmingham)Isabel Colmenero(Hospital Infantil Universitario Niño Jesús)Sarah E. CouplandNicholas C.P. Cross(University of Southampton)Daphne de Jong(Amsterdam University Medical Centers)M. Tarek Elghetany(Baylor College of Medicine)Emiko Takahashi(Aichi Medical University Hospital)Jean‐François Emile(Assistance Publique – Hôpitaux de Paris)Judith A. Ferry(Harvard University)Linda Fogelstrand(Sahlgrenska University Hospital)Michaëla Fontenay(Centre National de la Recherche Scientifique)Ulrich Germing(Heinrich Heine University Düsseldorf)Sumeet Gujral(Tata Memorial Hospital)Torsten Haferlach(Munich Leukemia Laboratory (Germany))Claire Harrison(Guy's and St Thomas' NHS Foundation Trust)Jennelle C. Hodge(Indiana University School of Medicine)Shimin Hu(The University of Texas MD Anderson Cancer Center)Joop H. Jansen(Radboud University Nijmegen)Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center)Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)Christian P. Kratz(Medizinische Hochschule Hannover)Xiaoqiu Li(Fudan University)Megan S. Lim(University of Pennsylvania)Keith R. Loeb(Fred Hutch Cancer Center)Sanam Loghavi(The University of Texas MD Anderson Cancer Center)Andrea N. Marcogliese(Baylor College of Medicine)Soheil Meshinchi(Fred Hutch Cancer Center)Phillip Michaels(Beth Israel Deaconess Medical Center)Kikkeri N. Naresh(Fred Hutch Cancer Center)Yasodha Natkunam(Stanford University)Reza Nejati(Fox Chase Cancer Center)German Ott(Robert Bosch Hospital)Eric Padron(Moffitt Cancer Center)Keyur P. Patel(The University of Texas MD Anderson Cancer Center)Nikhil Patkar(Tata Memorial Hospital)Jennifer Picarsic(Cincinnati Children's Hospital Medical Center)Uwe Platzbecker(University Hospital Leipzig)Irene Roberts(University of Oxford)Anna Schuh(University of Oxford)William A. Sewell(Garvan Institute of Medical Research)Reiner Siebert(Universität Ulm)Prashant Tembhare(Tata Memorial Hospital)Jeffrey Tyner(Oregon Health & Science University)Srđan Verstovšek(The University of Texas MD Anderson Cancer Center)Wei Wang(The University of Texas MD Anderson Cancer Center)Brent L. Wood(Children's Hospital of Los Angeles)Wenbin Xiao(Memorial Sloan Kettering Cancer Center)Cecilia C.S. Yeung(Fred Hutch Cancer Center)Andreas Hochhaus✉(Jena University Hospital)

View via DOI Full-text PDF

Abstract

The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.

Acute Myeloid Leukemia Research Histiocytic Disorders and Treatments Myeloproliferative Neoplasms: Diagnosis and TreatmentHistiocyteMyeloidDiseaseHematologic NeoplasmsMedicineComputational biologyComputer scienceBiologyPathologyImmunology